Analysis of Galectin-Binding Receptors on B Cells
Other Scholarly Work
Chakraborty, A, Mohammed, NBB, Bernasconi, AE et al. (2022). Analysis of Galectin-Binding Receptors on B Cells
. 2442 565-580. 10.1007/978-1-0716-2055-7_30
Chakraborty, A, Mohammed, NBB, Bernasconi, AE et al. (2022). Analysis of Galectin-Binding Receptors on B Cells
. 2442 565-580. 10.1007/978-1-0716-2055-7_30
The reported roles of the β-galactoside-binding lectin family, known as galectins, in disease development have been advancing at a remarkable pace. Galectins and their glycan counter-receptor ligands are now considered key functional determinants in malignant and metastatic progression, tumor immune evasion, autoimmunity, and immune homeostasis. Their influence in these processes is elicited through coordinated expression in tumor, immune and stromal cellular compartments. While analysis of galectin levels in related research efforts is routinely performed through immunoassays and RT-qPCR, detection, and identification of glycan counter-receptor ligands in their native form on the cell surface has lagged. In this report, we present methods to detect and identify glycan counter-receptor ligands to galectin (Gal)-3 and Gal-9—two galectins at the crosshairs of cancer and immunology research. As a model, we will describe (1) isolation of human B-cell subsets from fresh tonsil tissue, (2) assaying of Gal-3/-9-binding activities on human B cells, and (3) identifying Gal-3/-9 ligands on human B-cell surfaces. These methods, of course, can be implemented on any cell type to provide a cellular and molecular context capable of transmitting a galectin-mediated phenotype. Establishing a galectin-binding activity on specific counter-receptor ligand(s) can help unearth potential critical determinants capable of delivering cellular signals required for disease progression. These advances open new avenues of research investigation that result in novel therapeutic targets and approaches.
